Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 1.736
5-Year Impact Factor – 2.135
Index Copernicus  – 168.52
MEiN – 70 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2014, vol. 23, nr 4, July-August, p. 539–549

Publication type: original article

Language: English

Impact of Antiretroviral Therapy on Selected Metabolic Disorders – Pilot Study

Monika Bociąga-Jasik1,A,B,C,D,F, Anna Polus2,G, Joanna Góralska2,C,G, Urszula Raźny2,G, Dominika Siedlecka2,G, Barbara Zapała2,G, Robert Chrzan3,G, Aleksander Garlicki1,E, Tomasz Mach1,E, Aldona Dembińska-Kieć2,A,E,F

1 Chair of Gastroenterology, Hepatology and Infectious Diseases, Jagiellonian University, Collegium Medicum, Kraków, Poland

2 Department of Clinical Biochemistry, Jagiellonian University, Collegium Medicum, Kraków, Poland

3 Department of Radiology, Jagiellonian University, Collegium Medicum, Kraków, Poland


Background. Taking into consideration the aging of HIV infected individuals, changes in the metabolism aggravated by the antiretroviral therapy significantly impact their health. Mechanisms responsible for lipodystrophy, dyslipidemia and insulin resistance (IR) occurrence have not been completely understood. Only recently, the free fatty acids (FFAs) metabolic turnover has become considered to be the independent risk factor for cardiovascular complications.
Material and Methods. We designed the follow-up study in which patients were recruited before the introduction of ARV therapy and then observed up to 1 year. The impact of ARV therapy on the development of metabolic complications, inflammation markers and changes in adipokines secretion was investigated. The fasting and postprandial responses of FFAs, triglycerides (TG), glucose, insulin and glucose-dependent insulinotropic peptide (GIP) were measured. Changes in body composition were followed by impedance and a CT scan of adipose tissue volume of the abdomen and thighs.
Results. Significant impact of ARV therapy on metabolic disturbances was reported. Not only fasting, but also postprandial levels of FFAs and TG were found to increase during the follow up.
Conclusion. The increased concentration of FFAs is suggested to be the triggering event in the development of hypertriglyceridemia and insulin resistance during ARV therapy. Changes in postprandial FFAs and TG during the follow up indicate the increasing risk of cardiovascular diseases. We conclude that modern ARV therapy during the period of 12 months does not induce changes in the fat distribution, although increased limb fat correlated with higher plasma leptin level, which may be the marker of increased risk of metabolic driven cardiovascular complications.

Key words

adipokines, FFAs, GIP, HIV, IL-6, postprandial test, TNFα.

References (30)

  1. Volberding PA, Deeks SG: Antiretroviral therapy and management of HIV infection. Lancet 2010, 376, 49–62.
  2. Barbaro G, Iacobellis G: Metabolic syndrome associated with HIV and highly active antiretroviral therapy. Curr Diab Rep 2009, 9, 37–42.
  3. Gakhar H, Kamali A, Holodniy M: Health-related quality of life assessment after antiretroviral therapy: a review of the literature. Drugs 2013, 73, 651–672.
  4. Bociąga-Jasik M, Góralska J, Polus A, Śliwa A, Gruca A, Raźny U, Zdzienicka A, Garlicki A, Mach T, Dembińska-Kieć A: Mitochondrial Function and Apoptosis of Peripheral Mononuclear Cells (PBMCs) in the HIV Infected Patients. Curr HIV Res 2013, 11, 263–270.
  5. Kuller LH, Tracy R, Belloso W, De Wit S, Drummond F, Lane HC, Ledergerber B, Lundgren J, Neuhaus J, Nixon D, Paton NI, Neaton JD and INSIGHT SMART Study Group: Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 2008, 5, 203.
  6. Phillips AN, Carr A, Neuhaus J, Visnegarwala F, Prineas R, Burman WJ, Williams I, Drummond F, Duprez D, Belloso WH, Goebel FD, Grund B, Hatzakis A, Vera J, Lundgren JD: Interruption of antiretroviral therapy and risk of cardiovascular disease in persons with HIV-1 infection: exploratory analyses from the SMART trial. Antivir Ther 2008, 13, 177–187.
  7. Cruz-Teno C, Perez-Martinez P, Delgado-Lista J, Yubero-Serrano EM, Garcia-Rios A, Marin C, Gomez P, Jimenez-Gomez Y, Camargo A, Rodriguez-Cantalejo F, Malagon MM, Perez-Jimenez F, Roche HM, Lopez-Miranda J: Dietary fat modifies the postprandial inflammatory state in subjects with metabolic syndrome: the LIPGENE study. Mol Nutr Food Res 2012, 56, 854–865.
  8. Galescu O, Bhangoo A, Ten S: Insulin resistance, lipodystrophy and cardiometabolic syndrome in HIV/AIDS. Rev Endocr Metab Disord 2013, 14, 133–140.
  9. Fedorov A, Beichel R, Kalpathy-Cramer J, Finet J, Fillion-Robin JC, Pujol S, Bauer C, Jennings D, Fennessy F, Sonka M, Buatti J, Aylward S, Miller JV, Pieper S, Kikinis R: 3D Slicer as an image computing platform for the Quantitative Imaging Network. Magn Reson Imaging 2012, 30, 1323–1341.
  10. Tanaka A, Tomie N, Nakano T, Nakajima K, Yui K, Tamura M, Numano F: Measurement of postprandial remnant-like particles (RLPs) following a fat-loading test. Clin Chim Acta 1998, 275, 43–52.
  11. Guaraldi G, Stentarelli C, Zona S, Santoro A: HIV-Associated Lipodystrophy: Impact of Antiretroviral Therapy. Drugs 2013, 73, 1431–1450.
  12. Margolis AM, Heverling H, Pham PA, Stolbach A: A Review of the Toxicity of HIV Medications. J Med Toxicol 2013.
  13. Calmy A, Carey D, Mallon PW, Wand H, Law M, Cooper DA, Carr A: INITIO Trial International Co-ordinating Committee and HAMA study coordination team. Early changes in adipokine levels and baseline limb fat may predict HIV lipoatrophy over 2 years following initiation of antiretroviral therapy. HIV Med 2008, 9, 101–110.
  14. Sattler FR: Pathogenesis and treatment of lipodystrophy: what clinicians need to know. Top HIV Med 2008, 16, 127–133.
  15. Ugrinska A, Miladinova D, Trajkovska M, Zdravkovska M, Kuzmanovska S, Tripunoski T, Vaskova O: Correlation of serum leptin with anthropometric parameters and abdominal fat depots determined by ultrasonography in overweight and obese women. Prilozi 2013, 34, 115–119.
  16. McQuaid SE, Manolopoulos KN, Dennis AL, Cheeseman J, Karpe F, Frayn KN: Development of an arteriovenous difference method to study the metabolic physiology of the femoral adipose tissue depot. Obesity (Silver Spring) 2010, 18, 1055–1058.
  17. Paruthi J, Gill N, Mantzoros CS: Adipokines in the HIV/HAART-associated lipodystrophy syndrome. Metabolism 2013, 62, 1199–1205.
  18. Fardet L, Vigouroux C, Capeau J: Lipodystrophies. Rev Med Interne 2012, 614–622.
  19. Dube MC, Lemieux S, Piche ME, Corneau L, Bergeron J, Riou ME, Weisnagel SJ: Relationship of mid-thigh adiposity to the metabolic syndrome in postmenopausal women. Metab Syndr Relat Disord 2010, 8, 365–372.
  20. Levy AR, McCandless L, Harrigan PR, Hogg RS, Bondy G, Iloeje UH, Mukherjee J, Montaner JS: Changes in lipids over twelve months after initiating protease inhibitor therapy among persons treated for HIV/AIDS. Lipids Health Dis 2005, 4, 4.
  21. Mencarelli A, Francisci D, Renga B, D’Amore C, Cipriani S, Basile F, Schiaroli E, Baldelli F, Fiorucci S: Ritonavir-induced lipoatrophy and dyslipidaemia is reversed by the anti-inflammatory drug leflunomide in a PPAR-gamma-dependent manner. Antivir Ther 2012, 17, 669–678.
  22. Thomas-Geevarghese A, Raghavan S, Minolfo R, Holleran S, Ramakrishnan R, Ormsby B, Karmally W, Ginsberg HN, El-Sadr WM, Albu J, Berglund L: Postprandial response to a physiologic caloric load in HIVpositive patients receiving protease inhibitor-based or nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy. Am J Clin Nutr 2005, 82, 146–154.
  23. Goodpaster BH, Brown NF: Skeletal muscle lipid and its association with insulin resistance: what is the role for exercise? Exerc Sport Sci Rev 2005, 33, 150–154.
  24. Tateya S, Kim F, Tamori Y: Recent advances in obesity-induced inflammation and insulin resistance. Front Endocrinol (Lausanne) 2013, 4, 93.
  25. van Wijk JP, Cabezas MC, de Koning EJ, Rabelink TJ, van der Geest R, Hoepelman IM: In vivo evidence of impaired peripheral fatty acid trapping in patients with human immunodeficiency virus-associated lipodystrophy. J Clin Endocrinol Metab 2005, 90, 3575–3582.
  26. Magkos F, Fabbrini E, McCrea J, Patterson BW, Eagon JC, Klein S: Decrease in hepatic very-low-density lipoprotein-triglyceride secretion after weight loss is inversely associated with changes in circulating leptin. Diabetes Obes Metab 2010, 12, 584–590.
  27. Carpentier A, Patterson BW, Uffelman KD, Salit I, Lewis GF: Mechanism of highly active anti-retroviral therapy-induced hyperlipidemia in HIV-infected individuals. Atherosclerosis 2005, 178, 165–172.
  28. Yang ZH, Miyahara H, Iwasaki Y, Takeo J, Katayama M: Dietary supplementation with long-chain monounsaturated fatty acids attenuates obesity-related metabolic dysfunction and increases expression of PPAR gamma in adipose tissue in type 2 diabetic KK-Ay mice. Nutr Metab (Lond) 2013, 10, 16-7075-10-16.
  29. Escote X, Megia A, Lopez-Dupla M, Miranda M, Veloso S, Alba V, Domingo P, Pardo P, Vilades C, Peraire J, Giralt M, Richart C, Vendrell J, Vidal F and HIV-1 Lipodystrophy Study Group: A study of fatty acid binding protein 4 in HIV-1 infection and in combination antiretroviral therapy-related metabolic disturbances and lipodystrophy. HIV Med 2011, 12, 428–437.
  30. van Wijk JP, Hoepelman AI, de Koning EJ, Dallinga-Thie G, Rabelink TJ, Cabezas MC: Differential effects of rosiglitazone and metformin on postprandial lipemia in patients with HIV-lipodystrophy. Arterioscler Thromb Vasc Biol 2011, 31, 228–233.